Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • alexbmp
    Member
    • Oct 2011
    • 30

    #1

    Setting @RG ID, PL, PU, LB, SM etc.

    Hi all

    When running bwa, I want the read group information to be implanted so that I can use the information in picard and GATK later.

    I wrote down what I understood. Please point out if you think I'm wrong about something

    -I see that RG ID is a read discriminator; even when BAM files are merged thanks to RG ID the reads can be discriminated.

    -RG PL seems to be the sequencing machine platform (e.g. illumina).

    -RG LB seems to be referred by picard MarkDuplicates so PCR duplicates in each sequencing library can be removed.


    Now, I mention here that I read SAM-format spec.s.
    ( http://samtools.sourceforge.net/SAM1.pdf )
    However, I'm confused about 2 more things.

    1. Why does RG PU exist in the first place? Currently, the only reason I put in PU is to avoid picard and GATK errors later.

    2. What's the difference between RG ID and RG SM? Is there any sutble difference between the two?

    Thanks for your replies in advance!


    Have a great day
  • maubp
    Peter (Biopython etc)
    • Jul 2009
    • 1544

    #2
    SM is sample, and one sample might be sequenced twice, for instance with 454 and Illumina, which would be two read groups with different platform. At least, that is my understanding.

    Comment

    • alexbmp
      Member
      • Oct 2011
      • 30

      #3
      Thank you for your reply. So although I don't need the information right now, it can be important in some other pipeline I might take, right?

      Originally posted by maubp View Post
      SM is sample, and one sample might be sequenced twice, for instance with 454 and Illumina, which would be two read groups with different platform. At least, that is my understanding.

      Comment

      Latest Articles

      Collapse

      • SEQadmin2
        Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
        by SEQadmin2



        Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

        Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
        ...
        10-14-2026, 09:55 AM
      • SEQadmin2
        New Genomics Technologies Take Aim at Long-Standing Limits
        by SEQadmin2


        Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

        We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
        ...
        09-28-2026, 10:25 AM

      ad_right_rmr

      Collapse

      News

      Collapse

      Topics Statistics Last Post
      Started by SEQadmin2, 10-15-2026, 10:52 AM
      0 responses
      23 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-14-2026, 05:39 AM
      0 responses
      27 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-13-2026, 09:56 AM
      0 responses
      22 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-09-2026, 11:14 AM
      0 responses
      28 views
      0 reactions
      Last Post SEQadmin2  
      Working...